170 related articles for article (PubMed ID: 17072314)
1. Structure of the Epstein-Barr virus major envelope glycoprotein.
Szakonyi G; Klein MG; Hannan JP; Young KA; Ma RZ; Asokan R; Holers VM; Chen XS
Nat Struct Mol Biol; 2006 Nov; 13(11):996-1001. PubMed ID: 17072314
[TBL] [Abstract][Full Text] [Related]
2. Binding of the Epstein-Barr virus major envelope glycoprotein gp350 results in the upregulation of the TNF-alpha gene expression in monocytic cells via NF-kappaB involving PKC, PI3-K and tyrosine kinases.
D'Addario M; Ahmad A; Morgan A; Menezes J
J Mol Biol; 2000 May; 298(5):765-78. PubMed ID: 10801347
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr Virus and its glycoprotein-350 upregulate IL-6 in human B-lymphocytes via CD21, involving activation of NF-kappaB and different signaling pathways.
D'Addario M; Libermann TA; Xu J; Ahmad A; Menezes J
J Mol Biol; 2001 May; 308(3):501-14. PubMed ID: 11327783
[TBL] [Abstract][Full Text] [Related]
4. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).
Young KA; Chen XS; Holers VM; Hannan JP
J Biol Chem; 2007 Dec; 282(50):36614-25. PubMed ID: 17925391
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a 70-kDa, EBV gp350/220-binding protein on HSB-2 T cells.
Hedrick JA; Lao Z; Lipps SG; Wang Y; Todd SC; Lambris JD; Tsoukas CD
J Immunol; 1994 Nov; 153(10):4418-26. PubMed ID: 7963519
[TBL] [Abstract][Full Text] [Related]
6. Patterned entry and egress by Epstein-Barr virus in polarized CR2-positive epithelial cells.
Chodosh J; Gan Yj; Holder VP; Sixbey JW
Virology; 2000 Jan; 266(2):387-96. PubMed ID: 10639323
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the EBV/C3d receptor on the human Jurkat T cell line: evidence for a novel transcript.
Sinha SK; Todd SC; Hedrick JA; Speiser CL; Lambris JD; Tsoukas CD
J Immunol; 1993 Jun; 150(12):5311-20. PubMed ID: 8390533
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350.
Young KA; Herbert AP; Barlow PN; Holers VM; Hannan JP
J Virol; 2008 Nov; 82(22):11217-27. PubMed ID: 18786993
[TBL] [Abstract][Full Text] [Related]
9. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
Diefenbach RJ; Isenman DE
J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
[TBL] [Abstract][Full Text] [Related]
10. How Epstein-Barr virus envelope glycoprotein gp350 tricks the CR2? A molecular dynamics study.
Bingöl EN; Taştekil I; Yay C; Keskin N; Ozbek P
J Mol Graph Model; 2022 Jul; 114():108196. PubMed ID: 35500362
[TBL] [Abstract][Full Text] [Related]
11. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
[TBL] [Abstract][Full Text] [Related]
12. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.
Nemerow GR; Mold C; Schwend VK; Tollefson V; Cooper NR
J Virol; 1987 May; 61(5):1416-20. PubMed ID: 3033269
[TBL] [Abstract][Full Text] [Related]
13. Binding of the endogenously expressed Epstein-Barr virus (EBV) envelope glycoprotein gp350 with the viral receptor masks the major EBV-neutralizing epitope and affects gp350-specific ADCC.
Khyatti M; Ahmad A; Blagdon M; Frade R; Menezes J
J Leukoc Biol; 1998 Aug; 64(2):192-7. PubMed ID: 9715258
[TBL] [Abstract][Full Text] [Related]
14. Activation of the alternative complement pathway by EBV and the viral envelope glycoprotein, gp350.
Mold C; Bradt BM; Nemerow GR; Cooper NR
J Immunol; 1988 Jun; 140(11):3867-74. PubMed ID: 2836501
[TBL] [Abstract][Full Text] [Related]
15. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.
Sarrias MR; Franchini S; Canziani G; Argyropoulos E; Moore WT; Sahu A; Lambris JD
J Immunol; 2001 Aug; 167(3):1490-9. PubMed ID: 11466369
[TBL] [Abstract][Full Text] [Related]
16. The 15 SCR flexible extracellular domains of human complement receptor type 2 can mediate multiple ligand and antigen interactions.
Gilbert HE; Asokan R; Holers VM; Perkins SJ
J Mol Biol; 2006 Oct; 362(5):1132-47. PubMed ID: 16950392
[TBL] [Abstract][Full Text] [Related]
17. Characterization of C3dg binding to a recess formed between short consensus repeats 1 and 2 of complement receptor type 2 (CR2; CD21).
Prodinger WM; Schwendinger MG; Schoch J; Köchle M; Larcher C; Dierich MP
J Immunol; 1998 Nov; 161(9):4604-10. PubMed ID: 9794388
[TBL] [Abstract][Full Text] [Related]
18. Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2.
Martin DR; Yuryev A; Kalli KR; Fearon DT; Ahearn JM
J Exp Med; 1991 Dec; 174(6):1299-311. PubMed ID: 1660522
[TBL] [Abstract][Full Text] [Related]
19. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2).
Nemerow GR; Houghten RA; Moore MD; Cooper NR
Cell; 1989 Feb; 56(3):369-77. PubMed ID: 2464439
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of the purified Epstein Barr virus/C3d receptor (CR2) into liposomes and demonstration of its dual ligand binding functions.
Mold C; Cooper NR; Nemerow GR
J Immunol; 1986 Jun; 136(11):4140-5. PubMed ID: 3009615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]